A multicentric randomized phase II trial of CAPTEM (CT) or Folfiri (F) as second-line therapy in neuroendocrine carcinomas (NEC) and exploratory analysis of predictive role of PET imaging and biological markers (SENECA Study)

#3571

Introduction: No standard 2nd line treatment has been validated in patients (pts) with metastatic or locally advanced, non-resectable, grade 3 gastroenteropancreatic (GEP) and lung NEC after first-line platinum therapy. Furthemore more accurate prognostic biomarkers are needed.

Aim(s): To evaluate the activity and safety of FOLFIRI (F) or CAPTEM (CT) regimens as 2nd line in NEC pts. An exploratory study on circulating miRNA was performed.

Materials and methods: This is a randomised, non-comparative, multicentric phase II trial. A Bryant and Day study design was used and 25 pts were enrolled in the first step in each arm. All analyses have been performed separately for each arm.

Conference:

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Foca F, Bergamo F, Leo S, Pusceddu S,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, second line, Phase 2, NEC, Temozolomide, Capecitabine,